Shiseido account plan
Cosmetics and beauty products
At a glance
Shiseido is a Tokyo-listed prestige beauty group with FY2025 net sales of ¥970.0 bn and approx. 26,000 employees, now raising its 2026 profit forecast.
Shiseido Company, Limited (TSE: 4911) is a prestige beauty group founded in 1872 in Ginza, Tokyo. Its Core brands are SHISEIDO, Clé de Peau Beauté and NARS, and its Next brands include ELIXIR, ANESSA, fragrances and Dr. Dennis Gross Skincare. In FY2025 (year ended Dec. 31, 2025) it reported net sales of ¥970.0 bn, core operating profit of ¥44.5 bn and a net loss of ¥40.7 bn after a ¥46.8 bn goodwill impairment on the Americas Business. It had approx. 26,000 employees and is an independent, listed company led by CEO Kentaro Fujiwara.
Business units
China & Travel Retail Business
35.3% of 2025 net sales (¥342.2 bn)The largest segment, with core operating profit of ¥64.5 bn in 2025. Clé de Peau Beauté and NARS led growth in China and gained share, while Travel Retail stayed challenging. Led by Toshinobu Umetsu, CEO, China & Travel Retail Region.
Japan Business
30.4% of 2025 net sales (¥295.3 bn)Core brands expanded domestic market share for the third consecutive year, helped by the new ULTIMUNE from SHISEIDO and the ELIXIR wrinkle cream. Core operating profit was ¥39.0 bn. Led by Koji Nakata, CEO, Japan Region.
EMEA Business
14.5% of 2025 net sales (¥141.1 bn)Fragrance is the central category, with strong growth from narciso rodriguez and Zadig&Voltaire. Core operating profit was ¥3.9 bn, so improving fragrance profitability is a stated priority.
Americas Business
11.0% of 2025 net sales (¥106.6 bn)Core operating profit was -¥11.6 bn in 2025 as Drunk Elephant continued to face challenges. Cost structure reforms were completed, and priorities are a Drunk Elephant turnaround and fragrance growth.
Asia Pacific Business
7.6% of 2025 net sales (¥73.3 bn)Growth came from Southeast Asia, particularly Thailand, and South Korea. ELIXIR grew at strong double digits by moving into self-service channels including e-commerce. Led by Nicole Tan, CEO, Asia Pacific Region.
Strategic priorities
- 2030 financial targets
- Net sales CAGR of 2-5% (like-for-like, 2025-2030 average), a core operating profit margin of 10% or more, ROIC of 10% or more, ROE of 12% or more and free cash flow of ¥100.0 bn or more.
- Accelerate growth with brand power
- Concentrate on skincare and suncare, then makeup, fragrance, medical & derma and lifestyle. More than ten technologies are to be rolled out across brands by 2028, and Max Mara fragrance is planned for the second half of 2026.
- Evolve global operations
- Global optimization of the value chain, shorter lead times, brand and SKU reduction, and AI in formulation development and supply planning. A January 2026 reorganization added reporting lines from regional brand heads to global brand leadership.
- Dynamic resource allocation
- The CEO says budgets will be reallocated dynamically instead of fixed at the start of the year, with brands, regions and corporate functions sharing KPIs for sales, profit and brand value. A second product model aims to cut development time to about half, with launches from the first half of 2027.
- ROIC-driven financial discipline
- An Investment and Divestment Committee screens brand, IT and capex decisions, and ROIC is built into executive pay. Cash allocation for 2026-2030 targets capex of approx. ¥200.0 bn and dividends of approx. ¥130.0 bn.
Latest results
For the nine months to Sept. 30, 2026, net sales were ¥741,143 million (+6.8% YoY; like-for-like +0.7%) and core operating profit ¥67,458 million, up from ¥30,080 million. China & Travel Retail sales were ¥268,483 million and Japan ¥217,365 million. The company raised its FY2026 forecast to net sales of ¥1,025,000 million and core operating profit of ¥87,000 million (from ¥69,000 million), citing tariff refunds, the weaker yen and company-wide cost management. Like-for-like sales are expected to fall short of the previous forecast, with weak trends in Japan, EMEA, Americas and Asia Pacific.
Investments and deals
- Action Plan 2025-2026 cost programme
- Expected cost reductions of over ¥72.0 billion for 2024-2026, with ¥27.0 bn of savings in 2025 and more than ¥25.0 bn expected in 2026.
- Dr. Dennis Gross Skincare
- Acquired in 2024; cash outflows were ¥48.9 bn in 2024 and approx. ¥17.0 bn in 2026.
- Capex and IT
- Capex is 4.6% of sales in 2025, approx. 4% in 2026 and approx. 3% by 2030, as the FOCUS ERP rollout closes a cycle of major IT investment.
- People development
- Talent development investment is to rise to approximately three times the 2025 level over five years.
- Medical & derma and Beauty Checkup
- Expansion into medical & derma through physician collaboration in Japan and co-creation with aesthetic medicine institutions in China, plus Beauty Checkup services after Shiseido Beauty Park opened in January 2025.
Challenges and risks
- Sales growth lags profit
- The CEO says net sales growth is not satisfactory, and nine-month like-for-like growth was +0.7% against core operating profit of ¥67,458 million.
- Americas turnaround
- The Americas Business recorded a core operating loss of ¥11.6 bn in 2025 and a ¥46.8 bn goodwill impairment, and Drunk Elephant remains a drag.
- China and travel retail softness
- Consumer purchases in China were below the prior year in Q3 2026, ANESSA inventory is being optimized and Hong Kong is stagnating.
- High fixed costs
- The SG&A ratio remains above 70% even after Action Plan 2025-2026, and Japan has a high reliance on inbound sales.
- Supply and cyber risks
- The board cites procurement risk for petroleum-derived materials from Middle East tension, single-source materials and AI-leveraged cyberattacks.
What leadership says
“While our progress of profit generation has exceeded expectation, net sales growth is not satisfactory.”
“A drastic strategic review is not necessary, but rather, the operation to execute the strategy has to be changed”
“This is the final year of the Action Plan, and this is the first year of the midterm management strategy and a turning point for transformation.”
Where a supplier can help
- Supporting the second product model
- The plan to cut development time to about half and launch from the first half of 2027 suggests demand for formulation, packaging and supply partners that shorten lead times.
- Value-chain and AI tooling
- Pillar 2 targets lead-time reduction, SKU optimization and AI in supply planning and formulation, a fit for supply-chain planning, demand forecasting and data tools, especially where the FOCUS ERP is not yet deployed at some affiliates.
- Americas and EMEA go-to-market
- With the Americas turnaround, a Drunk Elephant reset and the Max Mara fragrance launch, suppliers of retail and e-commerce growth, marketing-return measurement and retailer data can tie into stated priorities.
- ROIC and cost optimization
- Cost savings of more than ¥25.0 bn in 2026 and the ROIC-based investment committee point to buyers of procurement, indirect spend and productivity solutions that show a clear return.
- AI visibility and customer experience
- The board is checking whether Shiseido's data is searchable and recommended by AI, which creates room for AI search visibility and CRM personalization services.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Shiseido?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Shiseido Integrated Report 2025 (fiscal year ended Dec. 31, 2025)
- Shiseido Company, Limited (TSE: 4911) is a Tokyo-based prestige beauty group founded in 1872 in Ginza as Japan's first private Western-style pharmacy; its core brands are SHISEIDO, Clé de Peau Beauté and NARS, with ELIXIR, ANESSA, fragrances and Dr. Dennis Gross Skincare as "Next" brands. It had approx. 26,000 employees.
- FY2025 (year ended Dec. 31, 2025): net sales ¥970.0 bn (like-for-like -2%), core operating profit ¥44.5 bn (4.6% margin, +22% YoY), net loss ¥40.7 bn after a ¥46.8 bn goodwill impairment on the Americas Business, free cash flow ¥66.5 bn versus -¥35.3 bn in 2024.
- Segments by 2025 net sales: China & Travel Retail ¥342.2 bn (35.3%), Japan ¥295.3 bn (30.4%), EMEA ¥141.1 bn (14.5%), Americas ¥106.6 bn (11.0%), Asia Pacific ¥73.3 bn (7.6%). The Americas lost ¥11.6 bn at core operating level, mainly because of Drunk Elephant.
- 2030 Medium-Term Strategy (announced November 2025): net sales CAGR of 2-5% (like-for-like, 2025-2030 average), core operating profit margin of 10% or more, ROIC of 10% or more, ROE of 12% or more and free cash flow of ¥100.0 bn or more; 2026 interim target is a 7% margin (core operating profit ¥69.0 bn).
- Three strategic pillars: Accelerate Growth with Brand Power (skincare and suncare first, then makeup, fragrance, medical & derma, lifestyle), Evolve Global Operations (FOCUS ERP, AI, new brand-region reporting lines) and Drive Sustainable Value Creation (people, DE&I, circular product design).
- Action Plan 2025-2026 delivered ¥27.0 bn of cost savings in 2025, with more than ¥25.0 bn expected in 2026; an Investment and Divestment Committee now screens brand, IT and capex decisions on ROIC, and ROIC is built into executive pay.
- Cash plan 2026-2030: operating cash flow of approx. ¥500.0-600.0 bn, capex approx. ¥200.0 bn (about 4% of sales in 2026, about 3% by 2030), dividends approx. ¥130.0 bn, net debt/EBITDA target of 0.5x; share buybacks and strategic M&A are options only in the latter half of the plan.
- CEO Kentaro Fujiwara (CEO since January 2025): "irreversible reform" is the top priority; the report names the Americas, high fixed costs (SG&A ratio still above 70% after the Action Plan), inbound dependence in Japan and geopolitics as open issues.
- Consolidated Settlement of Accounts for the Nine Months Ended September 30, 2026 [IFRS]
- Nine months to Sept. 30, 2026 (IFRS, published November 10, 2026): net sales ¥741,143 million (+6.8% YoY; FX-neutral +0.2%, like-for-like +0.7%); core operating profit ¥67,458 million (+124.3%), up from ¥30,080 million.
- Operating profit was ¥63,456 million versus a loss of ¥33,350 million a year earlier; profit attributable to owners of parent ¥44,385 million versus a loss of ¥43,983 million; EBITDA ¥106,162 million.
- By segment (net sales): China & Travel Retail ¥268,483 million (36.2%, +11.9%), Japan ¥217,365 million (29.3%, -0.8%), EMEA ¥106,099 million (14.3%), Americas ¥84,470 million (11.4%), Asia Pacific ¥58,167 million (7.8%).
- Core operating profit by segment: China & Travel Retail ¥59,839 million, Japan ¥34,213 million, Americas ¥5,636 million (a loss of ¥7,586 million a year earlier), Asia Pacific ¥5,454 million, EMEA a loss of ¥56 million.
- FY2026 forecast raised: net sales ¥1,025,000 million (from ¥990,000 million), core operating profit ¥87,000 million (from ¥69,000 million), profit attributable to owners of parent ¥62,000 million (from ¥42,000 million); like-for-like sales are expected to fall short of the previous forecast.
- The company cites tariff refunds, foreign exchange (yen depreciation) and company-wide cost management as drivers of the profit upgrade, plus "accelerated execution of asset-light initiatives".
- Operating cash flow ¥61.5 billion; equity ratio 50.5%; net debt-to-equity ratio 0.16; annual dividend forecast unchanged at ¥60 (¥30 interim paid, ¥30 year-end).
- Shiseido Q3 2026 Financial Results Briefing (English transcript)
- Q3 2026 results briefing, November 10, 2026 (English transcript of interpreted Japanese audio; CEO Kentaro Fujiwara and CFO Ayako Hirofuji): Fujiwara says "While our progress of profit generation has exceeded expectation, net sales growth is not satisfactory."
- Sales momentum: after a 3% decline in Q1, growth of 2% in Q2 and 3% in Q3 brought year-to-date like-for-like growth to 1%; net sales JPY741.1 billion and core operating profit JPY67.5 billion, a core operating margin of 9.1%.
- Full-year outlook: net sales raised to JPY1,025 billion on the weaker yen, core operating profit raised by JPY18 billion to JPY87 billion (margin 8.5% versus 7% previously); Fujiwara says the underlying margin excluding FX stands at 8%.
- 2030 goals unchanged: sales CAGR of 2% to 5%, core operating margin of 10% or more, ROIC of 10% or more, ROE of 12% or more and free cash flow of at least JPY100 billion; cumulative cost reduction of JPY72 billion achieved under the Action Plan.
- Fujiwara: "A drastic strategic review is not necessary, but rather, the operation to execute the strategy has to be changed": budgets will be reallocated dynamically, with brands, regions and corporate functions sharing KPIs (sales, profit, brand value); 2027 is "the year" the foundation turns into growth.
- A "second winning model" reuses 110 years of R&D assets to cut development time to about half; products launching from the first half of 2027. An investment and divestment committee sorts brands into four quadrants, with business transfers and withdrawal considered for the lower left.
- Regions: Japan consumer purchases up low single digit % locally while inbound consumer sales fell by a mid-teen percentage; China consumer purchases below prior year (ANESSA inventory being optimized, Hong Kong stagnating); Americas core operating profit JPY5.6 billion but Drunk Elephant underperforming; EMEA fragrance outpacing its market with Max Mara launched from September.
- Dialogue Between Shiseido's External Directors and Investors (English transcript)
- Webcast dialogue between external directors and investors on September 16, 2026 (English transcript of interpreted Japanese audio), with Yoshihiko Hatanaka (external director, Chair of the Board, Chair of the Nominating Committee) and Yasuhiro Nakajima (external director, Audit Committee member).
- Hatanaka: "This is the final year of the Action Plan, and this is the first year of the midterm management strategy and a turning point for transformation." The board stresses connecting structural reform to the growth path to 2030.
- Board view of 2026: profit is ahead of plan but sales lag: "We have seen that the profit was higher than we had expected, but not so much with the sales revenue", so investments for the second half are being reallocated.
- On the 2030 growth target of 2% to 5%, Hatanaka says "I don't think that it makes sense to be overly optimistic without a basis"; the Americas is among the "top challenges" and the board is pushing for a growth story there around the core 3 and next 5 brands.
- M&A: the board has reviewed past deals and concedes some acquisitions were not valuable; the lesson is that value creation after the acquisition and divestiture were not covered in a "holistic story line"; future M&A would start from a capability gap (medical derma and diagnostics were cited), not opportunistic shopping.
- Risk oversight: Middle East tension raised procurement risk for petroleum-derived raw materials; the board also watches single-source procurement, lead times and AI-enabled cyberattacks.
- Technology and AI: about 20 research themes are selected on when they create value; the FOCUS system investment has "settled" and is starting to return value, and the company monitors whether its data and technology are searchable and recommended by AI.
- Governance: three statutory committees since 2024; the board spent about half or the majority of its 2025 time on resource allocation; the corporate brand story is called "really weak" and the CEO is committed to fixing it.
Questions about Shiseido
What does Shiseido do?
Shiseido is a Tokyo-listed prestige beauty group founded in 1872. Its Core brands are SHISEIDO, Clé de Peau Beauté and NARS, and it also owns ELIXIR, ANESSA, fragrance brands and Dr. Dennis Gross Skincare.
How much revenue does Shiseido make?
FY2025 net sales were ¥970.0 bn with core operating profit of ¥44.5 bn. For the nine months to Sept. 30, 2026, net sales were ¥741,143 million, and the FY2026 forecast is ¥1,025,000 million.
How many employees does Shiseido have?
The 2025 integrated report lists approx. 26,000 employees.
What is Shiseido's strategy to 2030?
The 2030 Medium-Term Strategy targets a net sales CAGR of 2-5%, a core operating profit margin of 10% or more, ROIC of 10% or more, ROE of 12% or more and free cash flow of ¥100.0 bn or more, built on three pillars: brand power, global operations and sustainable value creation.
Who leads Shiseido?
Kentaro Fujiwara is Director, Representative Corporate Executive Officer, President and CEO since January 2025, and Ayako Hirofuji is Chief Financial Officer. Yoshihiko Hatanaka, an independent external director, chairs the Board.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-19)